REQUEST A DEMO
Total
USD $0.00
Search more companies

Diagnostimedicos y Drogas S.A.S. (Colombia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Diagnostimedicos y Drogas S.A.S. Profile Updated: May 13, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English & Spanish Download a sample report

Diagnostimedicos y Drogas S.A.S. is based in Colombia, with the head office in Bucaramanga. The company operates in the Drugs and Druggists' Sundries Merchant Wholesalers sector. It was incorporated on January 25, 2003. It currently has a total number of 34 (2026) employees. There was a net sales revenue drop of 0.36% reported in Diagnostimedicos y Drogas S.A.S.’s latest financial highlights for 2025. Its total assets grew by 14.42% over the same period. In, 2025, the company’s net profit margin decreased by 1.3%.

Headquarters
Calle 19 # 20-16
Bucaramanga; Santander;

Contact Details: Purchase the Diagnostimedicos y Drogas S.A.S. report to view the information.

Basic Information
Total Employees:
Purchase the Diagnostimedicos y Drogas S.A.S. report to view the information.
Financial Auditors:
Purchase the Diagnostimedicos y Drogas S.A.S. report to view the information.
Incorporation Date:
January 25, 2003
Key Executives
Purchase this report to view the information.
Legal Representative
Company Performance
Financial values in the chart are available after Diagnostimedicos y Drogas S.A.S. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency COP. Absolute financial data is included in the purchased report.
Net sales revenue
-0.36%
Total Operating Revenue
-0.36%
Net Profit/Loss for the Period
-28.37%
Total Assets
14.42%
Total Equity
14.68%
Net Profit Margin
-1.3%
Return on Equity (ROE)
-7.69%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?